[Evaluation of bone for using of bone metabolic markers in the diagnosis and treatment of osteoporosis].
Quantification of BMD is being used as the main method to diagnose osteoporosis and measurement accuracy has dramatically improved. However, essential clinical parameters of osteoporosis include more dynamic markers such as bone metabolic markers. Bone metabolism undergoes daily dynamic changes, and even with the same BMD, the metabolic state differs and the pathologic significance also differs. Therefore, to use BMD measurement as a dynamic marker, one must wait for an observation period of 6 months to 1 year before remeasurement, whereas bone metabolic markers accurately reflect the state of bone metabolism at the point in time of the measurement. Bone metabolic markers can also be used as a guide to selecting pharmacotherapy. When there is doubt about choosing a drug, the use of bone metabolic markers can enable more appropriate selection. Furthermore, to evaluate the effects of drug therapy on disease improvement, assessing the state of bone metabolism at the time of diagnosis is recommended whenever possible. However, if a decision is made to select treatment with little influence on bone metabolism, then measuring bone metabolic markers to monitor drug treatment effects has little clinical significance. Recently the clinical application of bone metabolic markers have been achieved significant progress and the measurements of these indices give us better understanding of pathological of osteoporosis. Therefore, it is very important to guide the proper application and assessment of bone metabolic markers in clinical practice.